AAV-mediated gene therapy for Sialidosis.

Area of Science:

• Biochemistry
• Genetics
• Molecular Biology

Background:

• Sialidosis is a rare genetic disorder caused by a deficiency in the lysosomal enzyme NEU1, leading to the accumulation of sialylated compounds.
• Current treatment options for sialidosis are limited, classifying it as an orphan disease with unmet therapeutic needs.

Approach:

• Adeno-associated virus (AAV)-mediated gene therapy was investigated in a mouse model of sialidosis (Neu1 mice).
• Mice received co-injection of AAV vectors expressing NEU1 and its chaperone PPCA.

Key Points:

• AAV gene therapy normalized NEU1 enzyme activity in treated mice.
• Histopathological analysis revealed reduced cellular vacuolization in organs and the brain.
• Sialyl-oligosacchariduria was reversed, and lysosomal exocytosis normalized in cerebrospinal fluid and serum.

Conclusions:

• AAV-mediated gene therapy effectively ameliorated sialidosis in a preclinical mouse model.
• This strategy shows promise for treating sialidosis and potentially other conditions like idiopathic fibrosis associated with low NEU1 expression.